Reparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
More Information Supplier Page
Reparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
More Information Supplier Page Reparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
More Information Supplier Page 
TCS-PIM-1-4a, a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).
More Information Supplier Page
TCS-PIM-1-4a, a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).
More Information Supplier Page TCS-PIM-1-4a, a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).
More Information Supplier Page 
Diroximel fumarate, a prodrug of monomethyl fumarate in a controlled-release formulation, rapidly and potently converts to MMF in the body.
More Information Supplier Page
Diroximel fumarate, a prodrug of monomethyl fumarate in a controlled-release formulation, rapidly and potently converts to MMF in the body.
More Information Supplier Page Diroximel fumarate, a prodrug of monomethyl fumarate in a controlled-release formulation, rapidly and potently converts to MMF in the body.
More Information Supplier Page 
LY2886721, a BACE inhibitor, is used for the therapy of Alzheimer’s Disease.
More Information Supplier Page
